THPP-1

• Product Name Alternative:

  Faropenem medoxil, 1-hydroxycholecalciferol-d7; 1.alpha.-Hydroxyvitamin D3-d7

• UNSPSC Description:

  THPP-1, a SGC chemical probe, is a potent and orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor, with Ki values of 1 nM and 1.3 nM for human and rat PDE10A, respectively. THPP-1 has excellent pharmacokinetic properties in preclinical species[1].

• Target Antigen:

  Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/thpp-1.html

• Purity:

  98.75

• Solubility:

  DMSO : 31.25 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=C2C=CC=CN2C=N1)N3CCC4=NC(C5=CC=C(N=C5)Cl)=NC(OCCOC)=C4C3

• Molecular Weight:

  464.90

• References & Citations:

  [1]Smith SM, et al. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. Neuropharmacology. 2013 Jan;64:215-23.|[2]Vardigan JD, et al. Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity. Psychopharmacology (Berl). 2016 Jul;233(13):2441-50.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1257051-63-0